Test Price
3,400 AEDโ Home Collection Available
Prenatal Chromosomal Microarray 60K with Karyotyping and FISH Chromosome 21 Analysis
Executive Summary & Core Metrics
- Diagnostic Sensitivity: 99.9% achieved through triple-modality analysis โ Chromosomal Microarray (Agilent 60K), G-Banding Karyotyping, and FISH Chromosome 21 โ processed at our ISO 9001:2015 certified facility.
- Collection Protocol: Hospital Extraction Only โ Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Ultrasound-guided amniocentesis or chorionic villus sampling performed by a DHA-licensed Maternal-Fetal Medicine specialist.
- Clinical Guidance: Complimentary post-test genetic counseling session with a senior genetics professional to interpret results, explain clinical implications, and coordinate follow-up care within 48 hours of report issuance.
- Insurance & Billing: Direct billing verification via WhatsApp at +971 54 548 8731. We interface with all major UAE insurers including DHA Thiqa, Enaya, and private networks for seamless pre-authorization.
Test Overview & Methodology
The Prenatal Chromosomal Microarray 60K with Karyotyping and FISH Chromosome 21 Analysis is the UAE's most comprehensive invasive prenatal genetic panel, integrating three orthogonal diagnostic technologies to detect aneuploidies, submicroscopic copy number variants, and structural chromosomal rearrangements in fetal DNA extracted from amniotic fluid or chorionic villi. This test is indicated for advanced maternal age, abnormal ultrasound findings, positive non-invasive screening results, and family history of chromosomal disorders.
Chromosomal Microarray detects submicroscopic deletions and duplications as small as 50โ100 kilobases that remain invisible to traditional karyotyping. G-Banding Karyotyping identifies large-scale structural rearrangements, aneuploidies, and balanced translocations through cultured fetal cell analysis. FISH Chromosome 21 uses fluorescent probes for rapid confirmation of Trisomy 21. Together these three techniques form the gold standard for invasive prenatal genetic diagnosis in the UAE.
| Parameter | Our Panel โ CMA 60K + Karyotyping + FISH | Standard Karyotyping Alone |
|---|---|---|
| Detection Resolution | Down to 50โ100 kb (CMA) + structural rearrangements (Karyotyping) + Chr 21 confirmation (FISH) | ~5โ10 Mb; misses submicroscopic CNVs |
| Methodology | CMA (Agilent 60K) + G-Banding + FISH (Triple-Modality) | G-Banding Karyotyping Only |
| Turnaround Time | 7โ9 Days | 14โ21 Days |
| Diagnostic Sensitivity | 99.9% | ~95% for large anomalies only |
| Sample Types Accepted | Amniotic Fluid, Chorionic Villi (CVS) | Amniotic Fluid, CVS, Whole Blood |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh โ Consultant Medical Genetics, DHA Registration ID: 9294403 โ states: "The integrated Chromosomal Microarray 60K panel combined with karyotyping and FISH for Chromosome 21 provides expectant families with the highest diagnostic clarity available for invasive prenatal genetic assessment. Every result must be interpreted within the full clinical context including detailed ultrasound findings and family pedigree analysis. Pre- and post-test genetic counseling is essential to ensure informed decision-making throughout the diagnostic journey."
This panel is a diagnostic tool, not a standalone clinical verdict. Genetic counseling is mandatory pre- and post-test in accordance with DHA Maternal-Fetal Medicine guidelines.
Critical Medication Advisory โ Do Not Discontinue Prescribed Therapy
If you are currently taking any prescribed medication โ including but not limited to anticoagulants, antiplatelet agents, immunosuppressants, or hormonal therapies โ do not discontinue or modify your dosage prior to this test without explicit consultation with your prescribing physician. Abrupt discontinuation may pose serious health risks independent of the prenatal diagnostic procedure.
Exclusion Criteria โ Before Scheduling Your Hospital Procedure
- Active Maternal Infection: Fever โฅ38ยฐC, untreated urinary tract infection, or systemic bacterial/viral illness within 7 days prior to scheduled amniocentesis or CVS.
- Bleeding Diathesis: Known coagulopathy, INR โฅ1.5, platelet count below 80,000/ยตL, or therapeutic anticoagulation that cannot be safely withheld per treating physician guidance.
- Placental Location Concerns: Complete placenta previa or anterior placenta with limited safe window for needle passage without expert sonographic mapping.
- Allergy to Local Anesthetic: Documented hypersensitivity to lidocaine or chloroprocaine used during the transabdominal procedure.
- Rhesus Sensitization Risk: Rh-negative mothers must receive Rh immunoglobulin prophylaxis immediately post-procedure; confirm availability prior to scheduling.
Emergency Red Flags โ Seek Immediate Medical Attention Post-Procedure
- Persistent vaginal bleeding or clear fluid leakage suggestive of amniotic membrane rupture
- Severe abdominal pain or cramping unrelieved by rest
- Fever โฅ38ยฐC or chills within 48 hours post-collection
- Decreased or absent fetal movement after 20 weeks gestation
- Uterine contractions occurring more than four times per hour
Patient FAQ & Clinical Guidance
1. What is the Prenatal Chromosomal Microarray 60K with Karyotyping and FISH Chromosome 21 test?
Direct Answer: This integrated prenatal genetic test combines three advanced technologies โ Chromosomal Microarray, G-Banding Karyotyping, and Fluorescence In-Situ Hybridization for Chromosome 21 โ to detect fetal chromosomal abnormalities with 99.9% diagnostic sensitivity.
The Chromosomal Microarray component detects submicroscopic deletions and duplications as small as 50โ100 kilobases that are invisible to traditional karyotyping. Karyotyping identifies large-scale structural rearrangements, aneuploidies, and balanced translocations through cultured fetal cell analysis. The FISH component specifically targets Chromosome 21 with fluorescent probes, providing rapid confirmation of Trisomy 21. Together, these three techniques form the gold standard for invasive prenatal genetic diagnosis, recommended for pregnancies with abnormal ultrasound markers or high-risk non-invasive screening results.
2. How is the sample collected and what is the turnaround time for results?
Direct Answer: Collected via ultrasound-guided amniocentesis or chorionic villus sampling by a DHA-licensed Maternal-Fetal Medicine specialist within a hospital setting. Comprehensive chromosomal results are delivered within seven to nine working days.
The sample collection procedure is performed as a minimally invasive transabdominal aspiration under continuous real-time ultrasound guidance to ensure precise needle placement and fetal safety. Amniocentesis is typically performed between 15โ20 weeks of gestation, while chorionic villus sampling is conducted between 11โ13 weeks. A local anesthetic is administered at the puncture site. The collected amniotic fluid or chorionic villus tissue is immediately transferred into sterile transport media and placed in an ISO-certified cold-chain container for rapid courier delivery to our genetics laboratory. Following cell culture, DNA extraction, and triple-modality analysis, a comprehensive report is issued within 7โ9 days.
3. Is a doctor's prescription required for this prenatal genetic test in the UAE?
Direct Answer: A valid prescription from a DHA-licensed Gynecologist, Maternal-Fetal Medicine Specialist, or Clinical Geneticist is mandatory for this advanced prenatal genetic diagnostic panel under UAE law.
In accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability and DHA Maternal-Fetal Medicine regulations, all invasive prenatal diagnostic procedures require a written prescription from a DHA-licensed specialist. This requirement ensures appropriate clinical indication, informed consent documentation, and medical necessity verification. The prescription must specify the test panel requested and include the referring physician's DHA license number. For insurance pre-authorization assistance or to verify your prescription's validity, contact our team via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Data Privacy Framework
All genomic data is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is encrypted, access-controlled, and never shared without explicit written consent.
Clinical Safety & Consent
Informed consent and clinical safety protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Every patient receives a detailed explanation of procedural risks, benefits, and alternatives before providing written consent. Genetic counseling is integrated into the care pathway.
Laboratory Accreditation
ISO 9001:2015 Certified โ Cert: INT/EGQ/2509DA/3139. DHA Facility License: 1143. All methodologies are validated against international genomic quality control standards. Results must be interpreted by a qualified healthcare provider in conjunction with complete clinical history and imaging findings.
Clinical & Logistical Metadata
| Test Name | Prenatal Chromosomal Microarray 60K with Karyotyping and FISH Chromosome 21 Analysis |
| Price (AED) | 3,400 |
| Turnaround Time | 7โ9 Working Days |
| Sample Type / Matrix | Amniotic Fluid, Chorionic Villi (CVS) โ Hospital Extraction Only |
| Methodology Used | CMA (Agilent 60K) + G-Banding Karyotyping + FISH Chromosome 21 |
| ICD-10-CM Code | Z36.86 |
| LOINC Code | 82128-6 |
| DHA Facility License & Address | License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians